GLYC Glycomimetics Inc
Price (delayed)
$0.2605
Market cap
$16.81M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.59
Enterprise value
$6.15M
GlycoMimetics is a biotechnology company with a focus in hematology-oncology and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate
Highlights
The debt has dropped by 92% year-on-year and by 74% since the previous quarter
The company's EPS rose by 4.8% QoQ
Glycomimetics's net income has increased by 4.7% QoQ but it has decreased by 2.7% YoY
The gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
Glycomimetics's revenue has plunged by 100% from the previous quarter and by 100% YoY
Key stats
What are the main financial stats of GLYC
Market
Valuations
Earnings
Shares outstanding
64.51M
Market cap
$16.81M
Enterprise value
$6.15M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.16
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$40.04M
Net income
-$37.88M
EBIT
-$37.88M
EBITDA
-$37.44M
Free cash flow
-$31.08M
Per share
Balance sheet
Liquidity
EPS
-$0.59
EPS diluted
-$0.59
Free cash flow per share
-$0.48
Book value per share
$0.08
Revenue per share
$0
TBVPS
$0.17
Total assets
$11.09M
Total liabilities
$5.78M
Debt
$66,844
Equity
$5.31M
Working capital
$5.31M
Debt to equity
0.01
Current ratio
1.92
Quick ratio
1.86
Net debt/EBITDA
0.28
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-177.4%
Return on equity
-230.7%
Return on invested capital
N/A
Return on capital employed
-712.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GLYC stock price
How has the Glycomimetics stock price performed over time
Intraday
-0.19%
1 week
18.41%
1 month
19.39%
1 year
-84.12%
YTD
4.62%
QTD
24.05%
Financial performance
How have Glycomimetics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$40.04M
Net income
-$37.88M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
Glycomimetics's revenue has plunged by 100% from the previous quarter and by 100% YoY
Glycomimetics's operating income has increased by 5% from the previous quarter
Glycomimetics's net income has increased by 4.7% QoQ but it has decreased by 2.7% YoY
Growth
What is Glycomimetics's growth rate over time
Valuation
What is Glycomimetics stock price valuation
P/E
N/A
P/B
3.16
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 4.8% QoQ
Glycomimetics's equity has plunged by 86% YoY and by 53% from the previous quarter
GLYC's price to book (P/B) is 76% higher than its 5-year quarterly average of 1.8 and 9% higher than its last 4 quarters average of 2.9
Glycomimetics's revenue has plunged by 100% from the previous quarter and by 100% YoY
Efficiency
How efficient is Glycomimetics business performance
Glycomimetics's return on assets has shrunk by 175% YoY and by 33% QoQ
The ROE has contracted by 43% from the previous quarter
Dividends
What is GLYC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GLYC.
Financial health
How did Glycomimetics financials performed over time
The total assets is 92% more than the total liabilities
The total assets has plunged by 76% YoY and by 29% from the previous quarter
GLYC's quick ratio has shrunk by 70% YoY and by 44% QoQ
The debt is 99% smaller than the equity
The debt has dropped by 92% year-on-year and by 74% since the previous quarter
Glycomimetics's equity has plunged by 86% YoY and by 53% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.